CDMO Idifarma wins Palobiofarma contract for clinical trials

By Flora Southey contact

- Last updated on GMT

(Image: Getty/MariaTkach)
(Image: Getty/MariaTkach)

Related tags: Spain, Contract manufacturing organisation

Idifarma’s seventh project with Palobiofarma will see the CDMO provide drug formulation, development and manufacturing services for respiratory disease candidate PBF-2987.

According to the agreement, contract development and manufacturing organisation (CDMO) Idifarma will prepare the compound for clinical trials from its EU good manufacturing practice (GMP) facility in Pamplona, Spain.

PBF-2897 is a novel co-crystal form of PBF-680, a candidate under investigation in Phase II clinical trials for the treatment of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

According to Idifarma, the PBF-2897 project – which is due to be completed next year – is the CDMO’s seventh with Spanish firm Palobiofarma.

“Palobiofarma and Idifarma have had a strong relationship for most of the decade, successfully working together on six projects since 2012, and this latest project extends and strengthens that relationship,” ​said Idifarma CEO Luis Oquiñena in a statement.

Palobiofarma similarly attested to firms’ strong working relationship: ”This latest agreement with Idifarma is testament to the successful collaboration between the two companies so far.

”Without them, it would not have been possible for Palobiofarma to successfully bring seven different novel drugs into clinical development,” ​said Palobiofarma CEO Julio Castro.

In January this year​, Idifarma announced plans to boost its spray drying services for highly potent drugs in response to growing demand. GEA’s Niro Mobile Minor spray drying technology came on line earlier at the CDMO’s Pamplona site earlier this month​.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more